CTMX—(+25%)—inks REGN drug-discovery collaboration—$30M up-front cash: https://www.globenewswire.com/news-release/2022/11/17/2558024/37704/en/CytomX-and-Regeneron-Announce-Strategic-Research-Collaboration-in-the-Field-of-Conditional-Bispecific-Therapeutics-for-the-Treatment-of-Cancer.html